Policy Statements, Position Papers or Practice Papers   

ACCP Public Policy Statements from 2015 to 2020 are listed below. Beginning in 2022 they are categorized as Policy Statements, Position Papers and Practice Papers. If you have questions please contact us at [email protected].

Position Papers

• ACCP Position Statement on Hydration and Vitamin Infusion Clinics
• Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action
• Prescription of Oral Contraceptives by Licensed Pharmacists in the USA

Position Papers

• The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct
  
• Over-the-Counter Epinephrine for Asthma Treatment: Too Much Risk for Too Little Benefit
• Drug Lawsuit Advertisements and the Importance of Physician Consultation Prior to Voluntary Medication Withdrawal or Transition
  
• The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials

 20

Position Papers

• Pharmacological Arguments Against the Use of Ketamine in Nonmedical Settings
  
• Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk-Benefit Profile
• Regulation of Dietary Supplements and Nutraceutical Products in the United States: An Argument for Greater Oversight and Uniform Standards
  
• Front-Line Health Care Professionals Lack Critical Knowledge in Dietary Supplement and Nutraceutical Products: A Call to Action for Comprehensive Educational Opportunities
  

• Statement of Support for US FDA: Science & Evidence-based Review and Approval of COVID-19 Vaccines for Use in the US
  
• ACCP Position Paper | Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action
  

• ACCP/CSRC Position Paper | The Potential Role of the J-T_peak Interval in Proarrhythmic Cardiac Safety
  

• Opportunistic Journals in the Clinical Pharmacology Space
  
• Are We Ready to Include Organ-Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent Recommendations
• Antibiotics Development and the Emergence of Resistance: Clinical Pharmacology to the Rescue

• Opioids for the Treatment of Pain: The Risk of Treating a Multivariate Symptom

• Edible Cannabis Products: It's Time for FDA Oversight 

 2015

• Exodus of Clinical Pharmacologists and Pharmacometricians From Academia—Who Is to Blame? A Policy Statement From the American College of Clinical Pharmacology^®

• A Dangerous Lack of Pharmacology Education in Medical and Nursing Schools: A Policy Statement From the American College of Clinical Pharmacology^®

• A Reality Check:The Need for a Deeper Understanding of Opioid Abuse Treatment Options:A Policy Statement From the American College of Clinical Pharmacology^®

• American College of Clinical Pharmacology^® Commentary on the Strategic Plan 2010–2014 Progress Report From the Office of Dietary Supplements, National Institutes of Health